Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Department of Health and Human Services Food and Drug Administration 21 CFR Parts 500, 510, 516, 520, 522, 524, 529, 556, and 558
[Docket No. FDA-2021-N-0002]
 AGENCY: Food and Drug Administration, HHS.
 ACTION: Final rule; technical amendments.
 SUMMARY: The Food and Drug Administration (FDA or we) is amending the animal drug regulations to reflect application-related actions for new animal drug applications (NADAs), abbreviated new animal drug applications (ANADAs), and a conditionally approved new animal drug application (cNADA) during July, August, and September 2021. FDA is informing the public of the availability of summaries of the basis of approval and of environmental review documents, where applicable. The animal drug regulations are also being amended to improve the accuracy of the regulations.
 DATES: This rule is effective February 28, 2022. The incorporation by reference of certain material listed in this rule is approved by the Director of the Federal Register as February 28, 2022. The incorporation by reference of other material listed in this rule was approved by the Director of the Federal Register as of November 25, 2011.
 FOR FURTHER INFORMATION CONTACT: George K. Haibel, Center for Veterinary Medicine (HFV-6), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 240-402-5689, 
                        *george.haibel@fda.hhs.gov.*


SUPPLEMENTARY INFORMATION:  I. Approvals FDA is amending the animal drug regulations to reflect approval actions for NADAs and ANADAs during July, August, and September 2021, as listed in table 1. In addition, FDA is informing the public of the availability, where applicable, of documentation of environmental review required under the National Environmental Policy Act (NEPA) and, for actions requiring review of safety or effectiveness data, summaries of the basis of approval (FOI Summaries) under the Freedom of Information Act (FOIA). These public documents may be seen in the office of the Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday, 240-402-7500. Persons with access to the internet may obtain these documents at the CVM FOIA Electronic Reading Room: 
                    *https://www.fda.gov/​about-fda/​center-veterinary-medicine/​cvm-foia-electronic-reading-room.*
                     Marketing exclusivity and patent information may be accessed in FDA's publication, “Approved Animal Drug Products Online (Green Book)” at: 
                    *https://www.fda.gov/​animal-veterinary/​products/​approved-animal-drug-products-green-book.* FDA has verified the website addresses as of the date this document publishes in the 
                    **Federal Register**
                    , but websites are subject to change over time.
                    ( print page 10965) Table 1—Original and Supplemental NADAs and ANADAs Approved During July, August, and September 2021
Approval date
File No.
Sponsor
Product name
Species
Effect of the action
Public 
                             documentsJuly 7, 2021
200-703
Dechra Veterinary Products LLC, 7015 College Blvd., Suite 525, Overland Park, KS 66211
Carprofen Tablets
Dogs
Original approval as a generic copy of NADA 141-053
FOI Summary.July 15, 2021
141-545
VetDC, Inc., 320 E Vine Dr., Suite 218, Fort Collins, CO 80524
TANOVEA (rabacfosadine for injection) Powder for Injection
Dogs
Full approval of conditionally approved cNADA 141-475 for the treatment of lymphoma
FOI Summary.August 2, 2021
200-708
Felix Pharmaceuticals PVT Ltd., 25-288 North Wall Quay, Dublin, 1, Ireland
Enrofloxacin Antibacterial Injectable Solution 2.27%
Dogs
Original approval as a generic copy of NADA 140-913
FOI Summary.August 16, 2021
200-618
Virbac AH, Inc., PO Box 162059, Fort Worth, TX 76161
ZOLETIL (tiletamine and zolazepam for Injection)
Dogs and cats
Original approval as a generic copy of NADA 106-111
FOI Summary.August 18, 2021
200-709
Cronus Pharma Specialties India Private Ltd., Sy No-99/1, M/s GMR Hyderabad Aviation SEZ Ltd., Mamidipalli Village, Shamshabad Mandal, Ranga Reddy, Hyderabad, Telangana, 501218, India
Amoxicillin and Clavulanate Potassium for Oral Suspension
Dogs and cats
Original approval as a generic copy of NADA 055-101
FOI Summary.August 19, 2021
141-063
Intervet, Inc., 2 Giralda Farms, Madison, NJ 07940
NUFLOR-S (florfenicol) Injectable Solution
Swine
Supplemental approval for the treatment of swine respiratory disease
FOI Summary.
 II. Withdrawal of Approval Elanco US Inc., 2500 Innovation Way, Greenfield, IN 46140, has requested that FDA withdraw approval of NADA 093-329 for use of a sustained-release bolus containing sulfamethazine in cattle because the product is no longer manufactured or marketed. As provided in the regulatory text of this document, the animal drug regulations are amended to reflect this action. Elsewhere in this issue of the 
                    **Federal Register**
                    , FDA gave notice that approval of NADA 093-329, and all supplements and amendments thereto, is withdrawn. III. Change of Sponsor VetDC, Inc., 320 E Vine Dr., Suite 218, Fort Collins, CO 80524, has informed FDA that it has transferred ownership of, and all rights and interest in, newly approved NADA 141-545 for TANOVEA (rabacfosadine) for Injection to Elanco US Inc., 2500 Innovation Way, Greenfield, IN 46140. The codification of this application in new 21 CFR 522.2065 will reflect this change of sponsorship. IV. Technical Amendments FDA is making the following amendments to improve the accuracy of the animal drug regulations: 21 CFR 500.1410 is amended to add uncooked edible tissues of swine to the standard for residues of 
                    *n*
                    -methyl-2-pyrrolidone.
                21 CFR 510.600 is amended to have sponsor addresses conform to the current style.
                21 CFR 520.905c is amended to reflect the current label indications for use of fenbendazole paste in horses.
                21 CFR 520.1044c is amended to reflect a current swine pathogen name for gentamicin soluble powder.
                21 CFR 520.1660d is amended to revise conditions of use of oxytetracycline in drinking water of swine to reflect approved applications.
                21 CFR 520.1780 is amended to revise the indications for use of pimobendan tablets in dogs.
                21 CFR 520.2130 is amended to remove the 90-milligram strength for spinosad chewable tablets.
                21 CFR 520.2220a is amended to add human food safety warnings for use of sulfadimethoxine concentrate solution and soluble powder.
                21 CFR 520.2260b is amended to reflect the voluntary withdrawal of approval of an application for sustained-release boluses containing sulfamethazine and to correct the spelling of a disease condition.
                21 CFR 520.2604 is amended to revise indications for use of tablets in dogs containing trimeprazine with prednisolone.
                21 CFR 522.558 is amended to reflect the drug labeler code for the current sponsor of a dexmedetomidine injectable solution.
                21 CFR 522.840 is amended to reflect the current classes of cattle approved for use of estradiol ear implants.
                21 CFR 522.842 for testosterone propionate and estradiol benzoate implants is renamed to list the drug with the higher concentration first and redesignated to be listed in alphabetical order.
                21 CFR 522.955 is amended to reflect the current scientific name of a bovine pathogen and the withdrawal 
                    ( print page 10966)
                    periods for different formulations of florfenicol injectable solution.
                21 CFR 522.1156 is amended to add subcutaneous administration to the approved conditions of use of imidocarb dipropionate solution in dogs.
                21 CFR 522.2477 is amended to reorganize an approved use of trenbolone acetate and estradiol implants in steers.
                21 CFR 524.770 is amended to reflect current label dosage information and human food safety warnings.
                21 CFR 529.1030 is redesignated as § 529.1004 in conformity with an announced FDA numbering system (40 FR 13802, March 27, 1975).
                21 CFR 529.1940 is amended to add limitations to the use of progesterone intravaginal inserts in cows.
                21 CFR 558.59 is amended to reference apramycin's status as a veterinary feed directive (VFD) drug and to add current limitations on VFD refills for apramycin medicated feeds.
                21 CFR 558.205 is amended to reflect a current egg food safety warning for broiler chickens and growing turkeys fed Type C medicated feeds containing diclazuril.
                21 CFR 558.254 is amended to remove an erroneous table title.
                21 CFR 558.261 is amended to correct the upper inclusion rate for florfenicol in Type C medicated feed for freshwater-reared salmonids.
                21 CFR 558.311 is being amended to codify free-choice Type C medicated cattle feeds containing lasalocid.
                21 CFR 558.450 is amended to add conditions of use in honey bees for a Type C extender patty containing oxytetracycline.
                21 CFR 558.633 is amended to add manufacturing limitations for use of Type C medicated swine feeds containing tylvalosin.
                21 CFR 558.635 is amended to reflect a current egg food safety warning for broiler chickens fed Type C medicated feeds containing virginiamycin and diclazuril. V. Incorporation by Reference FDA is incorporating by reference an analytical method approved by the Office of the Federal Register in accordance with 5 U.S.C. 552(a) and 1 CFR part 51. To obtain a copy of the analytical method, go to: 
                    *https://www.fda.gov/​about-fda/​center-veterinary-medicine/​cvm-foia-electronic-reading-room.*
                     You may inspect a copy at the office of the Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 240-402-7500, between 9 a.m. and 4 p.m., Monday through Friday. This standard adds a method of detection for total for residues of the carcinogenic excipient 
                    *n*
                    -methyl-2-pyrrolidone in uncooked edible swine tissues to a section established for a method for residues of 
                    *n*
                    -methyl-2-pyrrolidone in uncooked edible cattle tissues. VI. Legal Authority This final rule is issued under section 512(i) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C.360b(i)), which requires 
                    **Federal Register**
                     publication of “notice[s] . . . effective as a regulation,” of the conditions of use of approved new animal drugs. This rule sets forth technical amendments to the regulations to codify recent actions on approved new animal drug applications and corrections to improve the accuracy of the regulations, and as such does not impose any burden on regulated entities. Although denominated a rule pursuant to the FD&C Act, this document does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a “rule of particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808. Likewise, this is not a rule subject to Executive Order 12866, which defines a rule as “an agency statement of general applicability and future effect, which the agency intends to have the force and effect of law, that is designed to implement, interpret, or prescribe law or policy or to describe the procedure or practice requirements of an agency.” List of Subjects 21 CFR Part 500 Animal drugs
Animal feeds
Cancer
Incorporation by reference
Labeling
Packaging and containers
Polychlorinated biphenyls (PCBs) 21 CFR Part 510 Administrative practice and procedure
Animal drugs
Labeling
Reporting and recordkeeping requirements 21 CFR Part 516 Administrative practice and procedure
Animal drugs
Confidential business information
Reporting and recordkeeping requirements 21 CFR Parts 520, 522, 524, and 529 Animal drugs 21 CFR Part 556 Animal drugs
Food 21 CFR Part 558 Animal drugs
Animal feeds
 Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs, 21 CFR parts 500, 510, 516, 520, 522, 524, 529, 556, and 558 are amended as follows: PART 500—GENERAL
 1.The authority citation for part 500 continues to read as follows: Authority:
                        21 U.S.C. 321, 331, 342, 343, 348, 351, 352, 353, 360b, 371, 379e. 2.Revise § 500.1410 to read as follows: § 500.1410
  (a) 
                            *Standard for residues.*
                             No residues of 
                            *n*
                            -methyl-2-pyrrolidone may be found in the uncooked edible tissues of cattle and swine as determined by methods in paragraph (b) of this section. (b) 
                            *Incorporation by reference.*
                             The standards required in this section are incorporated by reference into this section with the approval of the Director of the Federal Register under 5 U.S.C. 552(a) and 1 CFR part 51. All approved material is available for inspection at the Food and Drug Administration's Dockets Management Staff (HFA-305), 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 240-402-7500, between 9 a.m. and 4 p.m., Monday through Friday. It may be obtained from the sources indicated elsewhere in paragraph (b) of this section and at: 
                            *https://www.fda.gov/​about-fda/​center-veterinary-medicine/​cvm-foia-electronic-reading-room.*
                             It is also available for inspection at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, email 
                            *fr.inspection@nara.gov,*
                             or go to: 
                            *www.archives.gov/​federal-register/​cfr/​ibr-locations.html.* (1) Food and Drug Administration, Center for Veterinary Medicine, 7500 Standish Pl., Rockville, MD 20855, 240-402-7002. (i) “Method of Analysis: 
                            *N*
                            -methyl-2-pyrrolidone,” September 26, 2011; the method of analysis for uncooked edible tissues of cattle. (ii) [Reserved] (2) Merck Animal Health, 29160 Intervet Lane, Millsboro, DE 19966, 1-800-211-3573. (i) “Determinative and Confirmatory Procedures for the Analysis of N-Methyl-2-pyrrolidone (NMP) in Swine Liver Tissue using LC-MS/MS,” July 20, 2017; the method of analysis for uncooked edible tissues of swine. (ii) [Reserved]
                            ( print page 10967) (c) 
                            *Related conditions of use.*
                             See §§ 522.814 and 522.955 of this chapter.
 PART 510—NEW ANIMAL DRUGS
 3.The authority citation for part 510 continues to read as follows: Authority:
                        21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e. § 510.600
 4.In § 510.600: a.In the table in paragraph (c)(1), revise the entries for “Anzac Animal Health, LLC”, “AquaBounty Technologies, Inc.”, “Dechra Veterinary Products LLC”, “Halocarbon Products Corp.”, “Kindred Biosciences, Inc.”, “Mizner Bioscience LLC”, “QBiotics Group Ltd.”, “Revivicor, Inc.”, and “Ridley USA, Inc.”, remove “Suite” and in its place add “suite”; and b.In the table in paragraph (c)(2), revise the entries for “012164”, “017033”, “067949”, “086039”, “086053”, “086073”, “086078”, “086132”, and “086134”. The revisions read as follows: (c) * * * (1) Alphabetical Listing of Sponsors
Firm name and address
Drug labeler code*         *         *         *         *         *         *Anivive Lifesciences, Inc., 3250 Airflite Way, Suite 400, Long Beach, CA 90807
086121Anzac Animal Health, LLC, 218 Millwell Dr., suite B, Maryland Heights, MO 63043
086073AquaBounty Technologies, Inc., 2 Mill and Main Pl., Suite 395, Maynard, MA 01754
086053*         *         *         *         *         *         *Dechra Veterinary Products LLC, 7015 College Blvd., Suite 525, Overland Park, KS 66211
017033*         *         *         *         *         *         *Halocarbon Products Corp., 6525 The Corners Pkwy., Suite 200, Peachtree Corners, GA 30092
012164*         *         *         *         *         *         *Kindred Biosciences, Inc., 1555 Bayshore Hwy., Suite 200, Burlingame, CA 94010
086078*         *         *         *         *         *         *Mizner Bioscience LLC, 225 NE Mizner Blvd., Suite 760, Boca Raton, FL 33432
086039*         *         *         *         *         *         *QBiotics Group Ltd., Suite 3A, Level 1, 165 Moggill Rd., Taringa, Queensland 4068, Australia
086132*         *         *         *         *         *         *Revivicor, Inc., a wholly owned subsidiary of United Therapeutics Corp., 1700 Kraft Dr., Suite 2400, Blacksburg, VA 24060
086134Ridley USA, Inc., 111 W Cherry St., Suite 500, Mankato, MN 56001
067949*         *         *         *         *         *         *
 (2) Numerical Listing of Sponsors
Drug labeler code
Firm name and address*         *         *         *         *         *         *012164
Halocarbon Products Corp., 6525 The Corners Pkwy., Suite 200, Peachtree Corners, GA 30092.*         *         *         *         *         *         *017033
Dechra Veterinary Products LLC, 7015 College Blvd., Suite 525, Overland Park, KS 66211.*         *         *         *         *         *         *067949
Ridley USA, Inc., 111 W Cherry St., Suite 500, Mankato, MN 56001.*         *         *         *         *         *         *086039
Mizner Bioscience LLC, 225 NE Mizner Blvd., Suite 760, Boca Raton, FL 33432.*         *         *         *         *         *         *086053
AquaBounty Technologies, Inc., 2 Mill and Main Pl., Suite 395, Maynard, MA 01754.*         *         *         *         *         *         *086073
Anzac Animal Health, LLC, 218 Millwell Dr., Suite B, Maryland Heights, MO 63043.086078
Kindred Biosciences, Inc., 1555 Bayshore Hwy., Suite 200, Burlingame, CA 94010.*         *         *         *         *         *         *086121
Anivive Lifesciences, Inc., 3250 Airflite Way, Suite 400, Long Beach, CA 90807.086132
QBiotics Group Ltd., Suite 3A, Level 1, 165 Moggill Rd., Taringa, Queensland 4068, Australia.086134
Revivicor, Inc., a wholly owned subsidiary of United Therapeutics Corp., 1700 Kraft Dr., Suite 2400, Blacksburg, VA 24060*         *         *         *         *         *         *
 PART 516—NEW ANIMAL DRUGS FOR MINOR USE AND MINOR SPECIES
 5.The authority citation for part 516 continues to read as follows: Authority:
                        21 U.S.C. 360ccc, 360ccc-2, 371. § 516.2065
 6.Remove § 516.2065. PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS
 7.The authority citation for part 520 continues to read as follows: Authority:
                        21 U.S.C. 360b. 8.Revise § 520.88h to read as follows: § 520.88h
  (a) 
                            *Specifications.*
                             When constituted, each milliliter (mL) of suspension contains amoxicillin trihydrate equivalent to 50 milligrams (mg) amoxicillin and clavulanate potassium equivalent to 12.5 mg clavulanic acid. (b) 
                            *Sponsors.*
                             See Nos. 054771 and 069043 in § 510.600(c) of this chapter. (c) 
                            *Conditions of use*
                            —(1) 
                            *Dogs*
                            —(i) 
                            *Amount.*
                             6.25 mg/lb (1 mL/10 lb of body weight) twice a day. Skin and soft tissue infections such as abscesses, cellulitis, wounds, superficial/juvenile pyoderma, and periodontal infections should be treated for 5 to 7 days or for 48 hours after all signs have subsided. If no response is seen after 5 days of treatment, therapy should be discontinued and the case reevaluated. Deep pyoderma may require treatment for 21 days; the maximum duration of treatment should not exceed 30 days. (ii) 
                            *Indications for use.*
                             Treatment of skin and soft tissue infections such as wounds, abscesses, cellulitis, superficial/juvenile and deep pyoderma due to susceptible strains of the following organisms: beta-lactamase-producing 
                            *Staphylococcus aureus,*
                             non-beta-lactamase-producing 
                            *Staphylococcus aureus, Staphylococcus*
                             spp., 
                            *Streptococcus*
                             spp., and 
                            *Escherichia coli.*
                             Treatment of periodontal infections due to susceptible strains of both aerobic and anaerobic bacteria. (iii) 
                            *Limitations.*
                             Federal law restricts this drug to use by or on the order of a licensed veterinarian. (2) 
                            *Cats*
                            —(i) 
                            *Amount.*
                             62.5 mg (1 mL) twice daily. Skin and soft tissue infections such as abscesses and cellulitis/dermatitis should be treated for 5 to 7 days or 48 hours after all symptoms have subsided, not to exceed 30 days. If no response is seen after 3 days of treatment, therapy should be discontinued and the case reevaluated. Urinary tract infections may require treatment for 10 to 14 days or longer. The maximum duration of treatment should not exceed 30 days. (ii) 
                            *Indications for use.*
                             Treatment of skin and soft tissue infections, such as wounds, abscesses, and cellulitis/dermatitis due to susceptible strains of the following organisms: beta-lactamase-producing 
                            *Staphylococcus aureus,*
                             non-beta-lactamase-producing 
                            *Staphylococcus aureus, Staphylococcus*
                             spp., 
                            *Streptococcus*
                             spp., 
                            *Escherichia coli, Pasteurella multocida,*
                             and 
                            *Pasteurella*
                             spp. Urinary tract infections (cystitis) due to susceptible strains of 
                            *E. coli.* (iii) 
                            *Limitations.*
                             Federal law restricts this drug to use by or on the order of a licensed veterinarian.
 9.In § 520.905c, revise paragraphs (e)(1)(i) to read as follows: § 520.905c
  
 (e) * * * (1) * * * (i) 
                            *Indications for use and amounts.*
                             (A) For the treatment and control of large strongyles (
                            *Strongylus edentatus, S. equinus,**S. vulgaris*), small strongyles, and pinworms (
                            *Oxyuris equi*). For large strongyles, small strongyles, and pinworms, the recommended dose is 5 mg/kg (2.3 mg/lb). (B) For treatment and control of ascarids (
                            *Parascaris equorum*). For ascarids, the recommended dose is 10 mg/kg (4.6 mg/lb). (C) For treatment and control of hypobiotic (encysted early third-stage), late third-stage, and fourth-stage cyathostome larvae, as well as fourth-stage 
                            *Strongylus vulgaris*
                             larvae, the recommended dose is 10 mg/kg (4.6 mg/lb) daily for 5 consecutive days. (D) For the control of arteritis caused by fourth-stage larvae of 
                            *Strongylus vulgaris*
                             in horses. (E) Fenbendazole paste 10 percent may be used concomitantly with approved forms of trichlorfon for the indications provided in paragraph (e)(1)(i)(A) of this section and for treating infections of stomach bots as provided in § 520.2520.
 10.In § 520.1044c, revise paragraph (d)(2) to read as follows: § 520.1044c
  
 (d) * * * (2) 
                            *Indications for use.*
                             For control and treatment of colibacillosis in weanling swine caused by strains of 
                            *Escherichia coli*
                             sensitive to gentamicin, and for control and treatment of swine dysentery associated with 
                            *Brachyspira hyodysenteriae.*
 11.In § 520.1660d, revise paragraphs (d)(1)(iii)(A) and (C) to read as follows: § 520.1660d
  
 (d) * * * (1) * * * (iii) * * * (A) 
                            *Amount.*
                             Administer 10 milligrams per pound of body weight daily in drinking water. Administer up to 14 days; do not use for more than 14 consecutive days those products sponsored by Nos. 054771, 061133, and 069254. Administer up to 5 days; do not use for more than 5 consecutive days those products sponsored by Nos. 016592 and 061133. 
 (C) 
                            *Limitations.*
                             Withdraw zero days prior to slaughter. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
 12.In § 520.1780, revise paragraph (c)(2) to read as follows: § 520.1780
  
 (c) * * * (2) 
                            *Indications for use.*
                             For the management of the signs of mild, moderate, or severe congestive heart failure in dogs due to clinical myxomatous mitral valve disease (MMVD) or dilated cardiomyopathy (DCM); for use with concurrent therapy for congestive heart failure (
                            *e.g.,*
                             furosemide, etc.) as appropriate on a case-by-case basis.
 13.In § 520.2130, revise paragraph (a) to read as follows: § 520.2130
  (a) 
                            *Specifications.*
                             Each chewable tablet contains 140, 270, 560, 810, or 1620 milligrams (mg) spinosad.
 14.In § 520.2220a, revise paragraphs (d)(1)(iii) and (d)(2)(iii) to read as follows: § 520.2220a
  
 (d) * * * (1) * * * (iii) 
                            *Limitations.*
                             Withdraw 5 days before slaughter. Do not administer to chickens over 16 weeks (112 days) of age. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
                            ( print page 10969) (2) * * * (iii) 
                            *Limitations.*
                             Withdraw 5 days before slaughter. Do not administer to turkeys over 24 weeks (168 days) of age. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
 § 520.2260b
 15.In § 520.2260b, remove and reserve paragraphs (b) and (e); and in paragraph (f)(2)(ii) remove “diptheria” and in its place add “diphtheria”. 16.In § 520.2604, revise paragraph (c)(2) to read as follows: § 520.2604
  
 (c) * * * (2) 
                            *Indications for use.*
                             For the relief of itching regardless of cause; and for reduction of inflammation commonly associated with most skin disorders of dogs such as eczema, caused by internal disorders, otitis, and dermatitis, allergic, parasitic, pustular, and nonspecific origins. As adjunctive therapy in various cough conditions including treatment of “kennel cough” or tracheobronchitis, bronchitis including allergic bronchitis, infections, and coughs of nonspecific origin.
 PART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS
 17.The authority citation for part 522 continues to read as follows: Authority:
                        21 U.S.C. 360b. § 522.558
 18.In § 522.558, in paragraph (b)(1), remove “026637” and in its place add “017033”. 19.In § 522.812, revise paragraph (b)(1) to read as follows: § 522.812
  
 (b) * * * (1) Nos. 016729, 017033, 055529, 058198, and 086101 for use of product described in paragraph (a)(1) as in paragraph (e)(1) of this section; and
 § 522.840
 20.In § 522.840, in paragraph (d)(2), in the first sentence, remove “confined steers and heifers” and in its place add “steers and heifers fed in confinement for slaughter”. § 522.842
 21.Redesignate § 522.842 as § 522.2343. 22.In § 522.955: a.Revise paragraph (b)(2); b.Redesignate paragraph (b)(3) as paragraph (b)(4) and add new paragraph (b)(3); c.In paragraphs (d)(1)(ii)(A)( *2*) and (d)(1)(ii)(B)(
                        *2*), remove “
                        *Haemophilus somnus”*
                         and in its place add “
                        *Histophilus somni”;* d.Revise paragraph (d)(1)(ii)(C); and e.Add paragraph (d)(2). The revisions and additions read as follows: § 522.955
  
 (b) * * * (2) No. 000061 for use of product described in paragraph (a)(2) of this section as in paragraphs (d)(1)(ii) and (d)(2) of this section. (3) No. 086050 for use of product described in paragraph (a)(2) of this section as in paragraph (d)(1)(ii) of this section. 
 (d) * * * (1) * * * (ii) * * * (C) 
                            *Limitations.*
                             Animals intended for human consumption must not be slaughtered within 28 days of the last intramuscular treatment. No. 000061: Animals intended for human consumption must not be slaughtered within 38 days of subcutaneous treatment. No. 055529: Animals intended for human consumption must not be slaughtered within 33 days of subcutaneous treatment. This product is not approved for use in female dairy cattle 20 months of age or older, including dry dairy cows. Use in these cattle may cause drug residues in milk and/or in calves born to these cows. A withdrawal period has not been established in pre-ruminating calves. Do not use in calves to be processed for veal. Federal law restricts this drug to use by or on the order of a licensed veterinarian. (2) Swine—(i) 300 mg/mL florfenicol in the inactive vehicles n-methyl-2-pyrrolidone, propylene glycol, and polyethylene glycol: (A) 
                            *Amount.*
                             15 mg/kg of body weight as an intramuscular injection. A second dose should be administered 48 hours later. (B) 
                            *Indications for use.*
                             For the treatment of swine respiratory disease associated with 
                            *Actinobacillus pleuropneumoniae, Pasteurella multocida,**Salmonella*
                             Choleraesuis, 
                            *Streptococcus suis, Bordetella bronchiseptica,*
                             and 
                            *Glaesserella (Haemophilus) parasuis*
                             in swine except for nursing piglets and swine of reproductive age intended for breeding. (C) 
                            *Limitations.*
                             Swine intended for human consumption must not be slaughtered within 11 days of the last intramuscular treatment. Federal law restricts this drug to use by or on the order of a licensed veterinarian. (ii) [Reserved]
 23.In § 522.1156, revise paragraph (c)(1) to read as follows: § 522.1156
  
 (c) * * * (1) 
                            *Amount.*
                             Administer 6.6 mg per kilogram (3 mg per pound) of body weight by intramuscular or subcutaneous injection. Repeat the dose after 2 weeks for a total of two treatments.
 24.Add § 522.2065 to read as follows: § 522.2065
  (a) 
                            *Specifications.*
                             Each vial of powder contains 16.4 milligrams (mg) rabacfosadine. Each milliliter of constituted solution contains 8.2 mg rabacfosadine. (b) 
                            *Sponsor.*
                             See No. 058198 in § 510.600(c) of this chapter. (c) 
                            *Conditions of use in dogs*
                            —(1) 
                            *Amount.*
                             Administer rabacfosadine at 1 mg/kilogram body weight as a 30-minute intravenous infusion, once every 3 weeks, for up to 5 doses. (2) 
                            *Indications for use.*
                             For the treatment of lymphoma in dogs. (3) 
                            *Limitations.*
                             Federal law restricts this drug to use by or on the order of a licensed veterinarian.
 25.Revise the section heading of newly designated § 522.2343 to read as follows: § 522.2343
 26.In § 522.2470, revise paragraph (b) introductory text to read as follows: § 522.2470
  
 (b) 
                            *Sponsors.*
                             See Nos. 026637, 051311, and 054771 in § 510.600(c) of this chapter.
 27.In § 522.2477, revise paragraph (b)(2), remove paragraph (d)(1)(i)(G), and add paragraph (d)(6) to read as follows: § 522.2477
  
 (b) * * *
                            ( print page 10970) (2) No. 000061 for use as in paragraphs (d)(1)(i)(A), (d)(1)(i)(C), (d)(1)(i)(D), (d)(1)(ii), (d)(1)(iii), (d)(2)(i)(A), (d)(2)(i)(C), (d)(2)(i)(D), (d)(2)(ii), (d)(2)(iii), (d)(3)(i)(A), (d)(3)(ii), (d)(3)(iii), (d)(4), (d)(5), and (d)(6) of this section. 
 (d) * * * (6) 
                            *Steers fed in confinement for slaughter—*
                            (i) 
                            *Amount.*
                             Each extended-release implant contains 200 mg trenbolone acetate and 40 mg estradiol (one implant consisting of 6 coated and 4 uncoated pellets, each containing 20 mg trenbolone acetate and 4 mg estradiol). (ii) 
                            *Indications for use.*
                             For increased rate of weight gain and improved feed efficiency for up to 200 days after implantation. (iii) 
                            *Limitations.*
                             Administer implant subcutaneously in the ear only. Do not use in lactating dairy cows or in animals intended for subsequent breeding. Use in these cattle may cause drug residues in milk and/or in calves born to these cows. A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves to be processed for veal. Effectiveness and animal safety in veal calves have not been established. Not approved for repeated implantation (reimplantation) with this or any other cattle ear implant during the production phase(s) identified on labeling (steers fed in confinement for slaughter) unless otherwise indicated on labeling because safety and effectiveness have not been evaluated.
 PART 524—OPHTHALMIC AND TOPICAL DOSAGE FORM NEW ANIMAL DRUGS
 28.The authority citation for part 524 continues to read as follows: Authority:
                        21 U.S.C. 360b. 29.In § 524.770, revise paragraphs (e)(1) and (e)(3) to read as follows: § 524.770
  
 (e) * * * (1) 
                            *Amount.*
                             Administer topically 1 mL (5 mg doramectin) per 22 lb (10 kg) of body weight. 
 (3) 
                            *Limitations.*
                             Cattle must not be slaughtered for human consumption within 45 days of treatment. Not for use in female dairy cattle 20 months of age or older. A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves to be processed for veal.
 PART 529—CERTAIN OTHER DOSAGE FORM NEW ANIMAL DRUGS
 30.The authority citation for part 529 continues to read as follows: Authority:
                        21 U.S.C. 360b. § 529.1030
 31.Redesignate § 529.1030 as § 529.1004. 32.In § 529.1940, revise paragraph (e)(1)(iii) to read as follows: § 529.1940
  
 (e) * * * (1) * * * (iii) 
                            *Limitations.*
                             Do not use in beef or dairy heifers of insufficient size or age for breeding or in animals with abnormal, immature, or infected genital tracts. Do not use in anestrous lactating dairy cows less than 42 days or greater than 78 days postpartum. Do not use in lactating dairy cows less than 40 days postpartum. Do not use in beef cows that are less than 20 days postpartum. Do not use an insert more than once. To prevent the potential transmission of venereal and bloodborne diseases, the inserts should be disposed after a single use. Administration of vaginal inserts for periods greater than 7 days may result in reduced fertility. Dinoprost injection for use in paragraphs (e)(1)(ii)(A) and (e)(1)(ii)(B) of this section as in § 522.690 of this chapter, as provided by No. 054771 in § 510.600(c) of this chapter.
 PART 556—TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD
 33.The authority citation for part 556 continues to read as follows: Authority:
                        21 U.S.C. 342, 360b, 371. 34.In § 556.710, revise paragraph (c) to read as follows: § 556.710
  
 (c) 
                            *Related conditions of use.*
                             See § 522.2343 of this chapter.
 PART 558—NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS
 35.The authority citation for part 558 continues to read as follows: Authority:
                        21 U.S.C. 354, 360b, 360ccc, 360ccc-1, 371. 36.In § 558.59, redesignate paragraph (d) as paragraph (e) and add new paragraph (d) to read as follows: § 558.59
  
 (d) 
                            *Special considerations.*
                             (1) Federal law restricts medicated feed containing this veterinary feed directive (VFD) drug to use by or on the order of a licensed veterinarian. See § 558.6 for additional requirements. (2) The expiration date of VFDs for apramycin medicated feeds must not exceed 6 months from the date of issuance. VFDs for apramycin shall not be refilled.
 37.In § 558.205, revise paragraphs (d)(1) and (2) to read as follows: § 558.205
  
 (d) * * * (1)
                            *Chickens.*
                             For chickens it is used as follows: Diclazuril
                                     grams/ton
Combination
                                     grams/ton
Indications for use
Limitations
Sponsor(i) 0.91

Broiler chickens: For the prevention of coccidiosis caused by 
                                    *Eimeria tenella, E. necatrix, E. acervulina, E. brunetti, E. mitis (mivati),*
                                     and 
                                    *E. maxima.*
                                     Because diclazuril is effective against 
                                    *E. maxima*
                                     later in its life cycle, subclinical intestinal lesions may be present for a short time after infection. Diclazuril was shown in studies to reduce lesion scores and improve performance and health of birds challenged with 
                                    *E. maxima*
Feed continuously as the sole ration. Do not feed to birds producing eggs for human consumption
058198( print page 10971)(ii) 0.91
Bacitracin methylenedisalicylate, 4 to 50
Broiler chickens: For the prevention of coccidiosis caused by 
                                    *Eimeria tenella, E. necatrix, E. acervulina, E. brunetti, E. mitis (mivati),*
                                     and 
                                    *E. maxima,*
                                     and for increased rate of weight gain and improved feed efficiency. Because diclazuril is effective against 
                                    *E. maxima*
                                     later in its life cycle, subclinical intestinal lesions may be present for a short time after infection. Diclazuril was shown in studies to reduce lesion scores and improve performance and health of birds challenged with 
                                    *E. maxima*
Feed continuously as the sole ration. Do not feed to birds producing eggs for human consumption. Bacitracin methylenedisalicylate provided by No. 054771 in § 510.600(c) of this chapter
058198(iii) 0.91
Bambermycins, 1 to 2
Broiler chickens: For the prevention of coccidiosis caused by 
                                    *Eimeria tenella, E. necatrix, E. acervulina, E. brunetti, E. mitis (mivati),*
                                     and 
                                    *E. maxima,*
                                     and for increased rate of weight gain and improved feed efficiency. Because diclazuril is effective against 
                                    *E. maxima*
                                     later in its life cycle, subclinical intestinal lesions may be present for a short time after infection. Diclazuril was shown in studies to reduce lesion scores and improve performance and health of birds challenged with 
                                    *E. maxima*
Feed continuously as the sole ration. Do not feed to birds producing eggs for human consumption. Bambermycins provided by No. 016592 in § 510.600(c) of this chapter
058198
 (2)
                            *Turkeys.*
                             For turkeys it is used as follows: Diclazuril
                                     grams/ton
Combination
                                     grams/ton
Indications for use
Limitations
Sponsor(i) 0.91

Growing turkeys: For the prevention of coccidiosis caused by 
                                    *Eimeria adenoeides, E. gallopavonis,*
                                     and
                                    *E. meleagrimitis*
Feed continuously as the sole ration. Do not feed to breeding turkeys. Do not feed to birds producing eggs for human consumption
058198(ii) 0.91
Bacitracin methylenedisalicylate, 4 to 50
Growing turkeys: For the prevention of coccidiosis caused by 
                                    *Eimeria adenoeides, E. gallopavonis,*
                                     and
                                    *E. meleagrimitis,*
                                     and for increased rate of weight gain and improved feed efficiency
Feed continuously as the sole ration. Do not feed to breeding turkeys. Do not feed to birds producing eggs for human consumption. Bacitracin methylenedisalicylate as provided by No. 054771 in § 510.600(c) of this chapter
058198(iii) 0.91
Bambermycins 1 to 2
Growing turkeys: For the prevention of coccidiosis caused by 
                                    *Eimeria adenoeides, E. gallopavonis,*
                                     and
                                    *E. meleagrimitis,*
                                     and for improved feed efficiency
Feed continuously as the sole ration. Do not feed to breeding turkeys. Do not feed to birds producing eggs for human consumption. Bambermycins as provided by No. 016592 in § 510.600(c) of this chapter
058198(iv) 0.91
Bambermycins 2
Growing turkeys: For the prevention of coccidiosis caused by 
                                    *Eimeria adenoeides, E. gallopavonis,*
                                     and
                                    *E. meleagrimitis,*
                                     and for increased rate of weight gain and improved feed efficiency
Feed continuously as the sole ration. Do not feed to breeding turkeys. Do not feed to birds producing eggs for human consumption. Bambermycins as provided by No. 016592 in § 510.600(c) of this chapter
058198
 § 558.254
 38.In § 558.254, in paragraph (e) introductory text, remove “Table 2—Size Proxies for SRCs in 2016”. 39.In § 558.261, revise paragraph (e)(2)(ii) to read as follows: § 558.261
  
 (e) * * * (2) * * * 
 
 Florfenicol in
                                     grams/ton of feed
Indications for use
Limitations*         *         *         *         *         *         *(ii) 182 to 1,816
Freshwater-reared salmonids: For the control of mortality due to coldwater disease associated with 
                                    *Flavobacterium psychrophilum*
                                     and furunculosis associated with 
                                    *Aeromonas salmonicida*
Feed as a sole ration for 10 consecutive days to deliver 10 to 15 mg florfenicol per kg of fish. Feed containing florfenicol shall not be fed for more than 10 days. Following administration, fish should be reevaluated by a licensed veterinarian before initiating a further course of therapy. The effects of florfenicol on reproductive performance have not been determined. Feeds containing florfenicol must be withdrawn 15 days prior to slaughter.*         *         *         *         *         *         *
 39.In § 558.311, add paragraph (e)(3)(ix) to read as follows: § 558.311
  
 (e) * * * (3) * * * Lasalocid amount
Indications for use
Limitations
Sponsor*         *         *         *         *         *         *(ix) 60 to 300 mg of lasalocid per head per day
Growing beef steers and heifers on pasture (stocker, feeder, and slaughter) and replacement beef and dairy heifers on pasture: For increased rate of weight gain
Feed continuously as a Type C free-choice medicated feed at a rate of 60 to 300 mg of lasalocid per head per day. Daily intakes of lasalocid in excess of 200 mg/head/day have not been shown to be more effective than 200 mg/head/day
054771
 40.In § 558.450, revise paragraph (e)(5)(ii), redesignate paragraphs (e)(5)(iii) through (vii) as paragraphs (e)(5)(iv) through (viii), and add new paragraph (e)(5)(iii) to read as follows: § 558.450
  
 (e) * * * (5) * * * Oxytetracycline amount
Indications for use
Limitations
Sponsor*         *         *         *         *         *         *(ii) 200 mg/colony as a dust (200 mg/oz) or syrup (200 mg/5 lb)
Honey bees: For control of American foulbrood caused by 
                                    *Paenibacillus larvae*
                                     and European foulbrood caused by 
                                    *Melissococcus plutonius*
                                     susceptible to oxytetracycline
Apply every 4 to 5 days for a total of three applications. Remove at least 6 weeks prior to main honey flow
066104
                                     069254(iii) 800 mg/colony as an extender patty (800 mg/patty)
Honey bees: For control of American foulbrood caused by 
                                    *Paenibacillus larvae*
                                     and European foulbrood caused by 
                                    *Melissococcus plutonius*
                                     susceptible to oxytetracycline
Use as a single application. Remove at least 6 weeks prior to main honey flow
066104
                                     069254*         *         *         *         *         *         *
 41.In § 558.633, revise paragraph (d)(3) to read as follows: § 558.633
  
 (d) * * * (3) An expiration date of 1 week is required for tylvalosin Type C medicated swine feeds in pelleted or crumbled form. Pelleted Type C medicated feeds must bear an expiration date of 30 days after the date of manufacture. Crumbled Type C medicated feeds must bear an expiration date of 7 days after the date of manufacture.
 42.In § 558.635, revise paragraph (e)(1)(iv) to read as follows: § 558.635
  
 (e) * * * (1) * * *
                            ( print page 10973) Virginiamycin
                                     in grams/ton
Combination
                                     in grams/ton
Indications for use
Limitations
Sponsor*         *         *         *         *         *         *(iv) 20
Diclazuril, 0.91
Broiler chickens: For prevention of necrotic enteritis caused by 
                                    *Clostridium perfringens*
                                     susceptible to virginiamycin; and for the prevention of coccidiosis caused by 
                                    *Eimeria tenella, E. necatrix, E. acervulina, E. brunetti, E. mitis*
                                     (
                                    *mivati),*
                                     and 
                                    *E. maxima.*
                                     Because diclazuril is effective against 
                                    *E. maxima*
                                     later in its life cycle, subclinical intestinal lesions may be present for a short time after infection. Diclazuril was shown in studies to reduce lesions scores and improve performance and health of birds challenged with 
                                    *E. maxima*
Feed continuously as the sole ration. Do not feed to birds producing eggs for human consumption. Diclazuril as provided by No. 058198 in § 510.600(c) of this chapter
058198*         *         *         *         *         *         *
 Dated: February 14, 2022. Lauren K. Roth, Associate Commissioner for Policy.


[FR Doc. 2022-03538 Filed 2-25-22; 8:45 am] BILLING CODE 4164-01-P